Obesity pill approved in the European Union. Who can use it and when will it arrive in Poland?

A new oral medication containing semaglutide has been approved in the EU for obesity treatment. It is intended for adults with a BMI of at least 27 and related health issues. Clinical trials showed participants lost an average of 13.6% of their body weight over 64 weeks. The medication requires specific intake guidelines and may cause gastrointestinal side effects. It will be gradually introduced in Poland starting in late 2026, but exact dates and pricing are not yet available.